Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

UPDATE2: Dow tops 30,000 for 1st time on transition hope, vaccine progress

11/24/2020 | 04:48pm EST

The Dow on Tuesday topped the 30,000 threshold for the first time as investors grew optimistic about the economic outlook following the start of the transition of power from U.S. President Donald Trump to President-elect Joe Biden and amid reports of progress toward COVID-19 vaccines.

The 30-issue Dow Jones Industrial Average soared 454.97 points, or 1.54 percent, to end at 30,046.24. The tech-heavy Nasdaq Composite Index rose 156.15 points, or 1.31 percent, to 12,036.79.

New York stocks opened higher as Trump finally gave the green light to start the transition process the previous day despite continuing his legal fight and other efforts to overturn the results of the Nov. 3 election, while Biden unveiled some members of his envisioned Cabinet.

Investors reacted positively as the Biden team gears up its preparations for the transition, with the belief that the incoming Democratic administration will reduce political risks compared with the incumbent Trump, whose government has featured unpredictable policy changes, traders said.

Recent progress in the development of vaccines for the novel coronavirus also helped stocks gain ground.

The University of Oxford and British drugmaker AstraZeneca Plc said Monday their vaccine candidate has shown up to 90 percent efficacy in trials. The announcement followed other promising results from U.S. drugmakers Moderna Inc. and Pfizer Inc.

Pfizer on Friday applied for emergency use authorization for its experimental coronavirus vaccine, marking a major step in the country's fight against the pandemic.

Moderna also said last week that its experimental vaccine was 94.5 percent effective in preventing COVID-19, the disease caused by the coronavirus.

The series of successful findings has raised hopes toward a breakthrough in the nearly year-long global fight against the coronavirus pandemic.

Despite surges in the numbers of infections and deaths in the United States, Europe and elsewhere, investors took heart from these reports as a sign of movement toward controlling the infectious disease, traders said.

"The stock market Dow Jones industrial average just hit 30,000 which is the highest in history," Trump said in the early afternoon. "And that's despite everything that's taken place with the pandemic, I'm very thrilled with what's happened on the vaccine front. That's been absolutely incredible."

Noting that the Dow had just exceeded the milestone, he said, "Never been broken, that number. That's a sacred number, 30,000. Nobody thought they'd ever see it."

"I just want to congratulate all the people within the administration that worked so hard. And most importantly I want to congratulate the people of our country, because there are no people like you," Trump added.

New York stocks remained firm throughout the day, with the Dow mostly staying above the 30,000 line in afternoon trading.

The sharp rise of the Dow comes as major equity markets in Europe as well as Japan rallied, with the bellwether Nikkei finishing at a 29-year high of 26,165.59 in Tokyo on Monday.

The Dow neared the 30,000 line in February, but the benchmark average went into a steep decline and fell below 19,000 in late March when the United States began to suffer stronger impacts from the pandemic.

As the U.S. government implemented stimulus measures and the Federal Reserve adopted a zero-interest rate monetary policy, however, U.S. stocks have risen gradually, pushing the Dow higher.


© Kyodo News International, Inc., source Newswire

Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 7.74% 134.858 Delayed Quote.19.79%
PFIZER INC. -0.48% 36.3374 Delayed Quote.-0.84%
All news about MODERNA, INC.
12:21pDON'T DOWNPLAY MRNA : Experts say new technology could change the vaccine landsc..
09:30aMODERNA : Says First Participant Dosed in COVID-19 Vaccine Phase 1/2 Study in Ja..
09:01aMODERNA : Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-..
08:58aTAKEDA PHARMACEUTICAL : Clinical study begins in Japan for Moderna's COVID-19 va..
08:34aMODERNA : Statement on California Department of Public Health (CDPH) Report
01:42aMobile labs take vaccine studies to diverse neighborhoods
01:42aMobile labs take vaccine studies to diverse neighbourhoods
01/20World Health Organization Nears Emergency Approval for Three COVID-19 Vaccine..
01/20McKesson to replace some Moderna COVID-19 vaccines due to low temperature
01/20Oxford scientists preparing vaccine versions to combat emerging virus variant..
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 -561 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -104x
Yield 2020 -
Capitalization 49 519 M 49 519 M -
EV / Sales 2020 91,8x
EV / Sales 2021 4,19x
Nbr of Employees 1 100
Free-Float 90,0%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 136,60 $
Last Close Price 125,14 $
Spread / Highest target 47,8%
Spread / Average Target 9,16%
Spread / Lowest Target -44,9%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.19.79%49 519
LONZA GROUP AG4.32%49 499
CELLTRION, INC.-13.09%38 562
SEAGEN INC.8.94%34 515